Basb207 polypeptides and polynucleotides from nontypeable haemophilus influenzae
CA 2426413 A1 · Owner: Glaxosmithkline Biologicals S.A. · Inventors: Thonnard, Joelle
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides nontypeable Haemophilus influenzae BASB207 polypeptides and polynucleotides encoding BASB207 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic prophylactic and therapeutic uses, including vaccines against bacterial infections.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 16, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 16, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 16, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.